What is the estimated risk of malignancy in a postmenopausal woman with an ovarian cyst and a Risk of Malignancy Index (RMI) less than 200?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk of Malignancy with RMI <200 in Postmenopausal Ovarian Cysts

When the Risk of Malignancy Index (RMI) is calculated as less than 200 in a postmenopausal woman with an ovarian cyst, the risk of malignancy is generally low, typically in the range of 1-10%, though the precise risk depends critically on the ultrasound morphology of the cyst. 1

Understanding RMI <200 in Clinical Context

The RMI threshold of 200 is commonly used as a cutoff to distinguish low-risk from high-risk ovarian masses, with values below 200 suggesting lower malignancy risk. 1 However, the actual malignancy risk varies substantially based on the specific ultrasound characteristics of the cyst, which is why modern risk stratification systems like O-RADS have largely superseded RMI alone. 1

Risk Stratification by Cyst Morphology (RMI <200)

When RMI is <200, the malignancy risk breaks down as follows based on ultrasound features:

  • Simple unilocular cysts ≤3 cm: Essentially 0% malignancy risk, with no cases of malignancy reported in large screening studies 1, 2

  • Simple unilocular cysts 3-10 cm: <1% malignancy risk (O-RADS 2 category), with only 1 out of 2,349 simple cysts (0.04%) proving malignant at 3-year follow-up in a landmark study of 72,093 women 2, 3

  • Unilocular cysts with irregular inner wall or multilocular smooth cysts <10 cm: 1-10% malignancy risk (O-RADS 3 category) 1

  • Complex cysts with wall abnormalities or solid areas: 10-50% malignancy risk (O-RADS 4 category), even when RMI is <200 1, 4

Critical Warning Signs That Elevate Risk Despite Low RMI

Even with RMI <200, certain ultrasound features substantially increase malignancy risk and require escalated management:

  • Developing vascularity within previously avascular lesions on color Doppler imaging 1, 2
  • Changing morphology on serial imaging (e.g., developing septations or solid components) 5, 2
  • Cyst enlargement over time during surveillance 2
  • Size >10 cm in maximum diameter 1, 2
  • Presence of ascites in conjunction with the cyst 1
  • Papillary projections or solid nodules with blood flow 1

Management Algorithm for RMI <200

For simple cysts:

  • ≤3 cm: No follow-up required 1, 2
  • 3-10 cm: Follow-up ultrasound at 8-12 weeks, then annually if stable 1, 2
  • 10 cm: Gynecologic referral or MRI evaluation 1

For septated/multilocular cysts without solid components:

  • Referral to ultrasound specialist, gynecologist, or MRI for further characterization 1, 5
  • Annual ultrasound surveillance if diagnosis is confident and <10 cm 5

For any cyst with solid components or vascularity:

  • Direct MRI with contrast (if feasible) and gynecologic oncology consultation, regardless of RMI value 1, 2

Important Caveats

CA-125 alone (a component of RMI) performs worse than ultrasound in distinguishing benign from malignant lesions, as it may be low with low-grade and low malignant potential lesions. 1 CA-125 levels improve specificity only in lesions already suspected to be malignant on ultrasound. 1

Hemorrhagic cysts should not occur in postmenopausal women, so if typical hemorrhagic features are seen, further evaluation by ultrasound specialist, gynecologist, or MRI is required even with low RMI. 5, 2

Endometriomas have higher risk of malignant transformation to clear cell and endometrioid carcinomas in postmenopausal women, warranting annual ultrasound surveillance when not surgically excised. 5, 2

The most common pitfall is failing to compare with previous imaging, which can lead to missing subtle changes indicating malignant transformation despite reassuring RMI values. 5, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Risk of Malignancy in Postmenopausal Ovarian Cysts

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Risk Assessment of Second Multiloculated Septated Ovarian Cyst in Postmenopausal Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.